HomeInsightsStock Comparison

Novartis India Ltd vs Sun Pharmaceutical Industries Ltd Stock Comparison

Novartis India Ltd vs Sun Pharmaceutical Industries Ltd Stock Comparison

Last Updated on: Apr 25, 2025

Key Highlights

  • The Latest Trading Price of Novartis India Ltd is ₹ 818.35 as of 25 Apr 15:30.
  • The P/E Ratio of Novartis India Ltd changed from 0 on March 2020 to 0 on March 2024 . This represents a CAGR of 0.0% over 5 yearsThe P/E Ratio of Sun Pharmaceuticals Industries Ltd changed from 22.5 on March 2020 to 40.6 on March 2024 . This represents a CAGR of 12.53% over 5 years.
  • The Market Cap of Novartis India Ltd changed from ₹ 0 crore on March 2020 to ₹ 0 crore on March 2024 . This represents a CAGR of 0.0% over 5 yearsThe Market Cap of Sun Pharmaceuticals Industries Ltd changed from ₹ 84504 crore on March 2020 to ₹ 388812 crore on March 2024 . This represents a CAGR of 35.70% over 5 years.
  • The revenue of Novartis India Ltd for the Dec '24 is ₹ 0 crore as compare to the Sep '24 revenue of ₹ 0 crore. This represent the decline of 0% The revenue of Sun Pharmaceuticals Industries Ltd for the Dec '24 is ₹ 14141 crore as compare to the Sep '24 revenue of ₹ 13645 crore. This represent the growth of 3.63%.
  • The ebitda of Novartis India Ltd for the Dec '24 is ₹ 0 crore as compare to the Sep '24 ebitda of ₹ 0 crore. This represent the decline of 0% The ebitda of Sun Pharmaceuticals Industries Ltd for the Dec '24 is ₹ 4158 crore as compare to the Sep '24 ebitda of ₹ 4292 crore. This represent the decline of -3.13%.
  • The net profit of Novartis India Ltd changed from ₹ 0 crore to ₹ 0 crore over 7 quarters. This represents a CAGR of 0.0% The net profit of Sun Pharmaceuticals Industries Ltd changed from ₹ 2013 crore to ₹ 2917 crore over 7 quarters. This represents a CAGR of 23.62% .
  • The Dividend Payout of Novartis India Ltd changed from 244.84 % on March 2020 to 72.43 % on March 2024 . This represents a CAGR of -21.62% over 5 yearsThe Dividend Payout of Sun Pharmaceuticals Industries Ltd changed from 29.89 % on March 2020 to 113.33 % on March 2024 . This represents a CAGR of 30.55% over 5 years.

Share Price

* All values are in Rupees

P/E Ratio Over Time

No data available

Market Cap Over Time

No data available

* All values are in crore

Historical Share Prices

* All values are in Rupees

Revenue Over Time

No data available

* All values are in crore

EBITDA Over Time

No data available

* All values are in crore

Net Profit Over Time

No data available

* All values are in crore

Dividend Payout Over Time

No data available

* All values are in %

About Novartis India Ltd

  • Novartis India Limited (NIL) is a subsidiary of Swiss giant Novartis, the world's second largest pharmaceutical company was incorporated on 13 December 1947.
  • The Company is engaged in manufacturing and marketing of drugs, pharmaceutical products and formulations for consumer healthcare and animal healthcare; it operates into four segments such as Pharmaceuticals, Generics, Over the Trade Counter and Animal Health. The origin of Novartis is linked to the origin of three distinct companies namely Geigy, Ciba, and Sandoz.
  • The history of Geigy goes back to the middle of the 18th century, Ciba was founded around 1860, and Sandoz was set-up in 1886.
  • In 1970 Ciba and Geigy merged to form Ciba-Geigy Ltd. Sandoz and Ciba-Geigy Ltd continued as separate entities for the next 25 years.
  • In 1996, in one of the largest corporate mergers in history Sandoz and Ciba-Geigy Ltd.

About Sun Pharmaceuticals Industries Ltd

  • Sun Pharmaceutical Industries Limited including its subsidiaries and associates is the fourth largest global specialty generic company that is ranked No. 1 in India and No. 8 in the US. It is the largest Indian pharmaceutical company in the US and among the leading Indian pharmaceutical companies in emerging markets.
  • The company manufactures and markets a large basket of pharmaceutical formulations covering a broad spectrum of chronic and acute therapies.
  • It includes generics, branded generics, complex or difficult to make technology intensive products, over-the-counter (OTC) products, anti-retrovirals (ARVs), Active Pharmaceutical Ingredients (APIs) and intermediates.
  • The product portfolio of over 2000 high quality molecules covers multiple dosage forms, including tablets, capsules, injectables, sprays, inhalers, drug delivery systems, ointments, creams and liquids.

Novartis India Ltd News Hub

News

Novartis India to announce Quarterly Result

Novartis India will hold a meeting of the Board of Directors of the Company on 9 May 2025....

Read more

28 Mar 2025 09:32

News

Novartis India to hold board meeting

Novartis India will hold a meeting of the Board of Directors of the Company on 28 January ...

Read more

28 Dec 2024 09:37

News

Novartis India schedules board meeting

Novartis India will hold a meeting of the Board of Directors of the Company on 25 October ...

Read more

28 Sep 2024 10:07

News

Novartis India to declare Quarterly Result

Novartis India will hold a meeting of the Board of Directors of the Company on 29 July 202...

Read more

28 Jun 2024 17:50

News

Novartis India to conduct AGM

Novartis India announced that the 76th Annual General Meeting(AGM) of the company will be ...

Read more

11 May 2024 11:58

News

Board of Novartis India recommends Final Dividend

Novartis India announced that the Board of Directors of the Company at its meeting held on...

Read more

10 May 2024 17:41

Sun Pharmaceuticals Industries Ltd News Hub

News

Sun Pharma and Israel-based Moebius Medical publish two articles on MM-II

Sun Pharmaceutical Industries and Israel-based Moebius Medical announced today the publica...

Read more

24 Apr 2025 09:12

News

Sun Pharmaceutical launches Fexuprazan tablets 40 mg in India

Sun Pharmaceutical Industries has launched Fexuprazan tablets 40 mg in India under the bra...

Read more

07 Apr 2025 09:07

News

Sun Pharma launches Fexuprazan tablets 40 mg in India

The drug, available in 40 mg tablets, is approved as a new treatment for adults with erosi...

Read more

07 Apr 2025 10:23

News

Sun Pharma completes acquisition of Antibe Therapeutics Inc., Canada

Sun Pharmaceutical Industries has completed 100% acquisition of Antibe Therapeutics Inc., ...

Read more

18 Mar 2025 15:01

News

Sun Pharma gains as arm acquires Antibe Therapeutics for $4.5 Million

Sun Pharmaceuticals Industries is a leading global pharmaceutical company with a specialty...

Read more

18 Mar 2025 12:53

News

Sun Pharmaceuticals Industries Ltd soars 0.96%, gains for fifth straight session

Sun Pharmaceuticals Industries Ltd rose for a fifth straight session today. The stock is q...

Read more

17 Mar 2025 13:00

SWOT Analysis Of Novartis India Ltd

Strength

1

S

Weakness

0

W

Opportunity

0

O

Threats

0

T

SWOT Analysis Of Sun Pharmaceuticals Industries Ltd

Strength

2

S

Weakness

2

W

Opportunity

0

O

Threats

1

T

BlinkX Score for Novartis India Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

BlinkX Score for Sun Pharmaceuticals Industries Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

FAQs for the comparison of Novartis India Ltd and Sun Pharmaceuticals Industries Ltd

Which company has a larger market capitalization, Novartis India Ltd or Sun Pharmaceuticals Industries Ltd?

Market cap of Novartis India Ltd is 2,020 Cr while Market cap of Sun Pharmaceuticals Industries Ltd is 428,725 Cr

What are the key factors driving the stock performance of Novartis India Ltd and Sun Pharmaceuticals Industries Ltd?

The stock performance of Novartis India Ltd and Sun Pharmaceuticals Industries Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Novartis India Ltd and Sun Pharmaceuticals Industries Ltd?

As of April 25, 2025, the Novartis India Ltd stock price is INR ₹818.35. On the other hand, Sun Pharmaceuticals Industries Ltd stock price is INR ₹1786.85.

How do dividend payouts of Novartis India Ltd and Sun Pharmaceuticals Industries Ltd compare?

To compare the dividend payouts of Novartis India Ltd and Sun Pharmaceuticals Industries Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.
Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.
up arrow
Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions

Join the

Future of Trading

with BlinkX

#ItsATraderThing

Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions